Effect of renal impairment on the pharmacokinetics of intravenous zanamivir

Clinical Pharmacokinetics

Volumn 36, Issue SUPPL. 1, 1999, Pages 13-19

  Cass, Lindsey M R ^a   Efthymiopoulos, Constantin ^a   Marsh, Julie ^a   Bye, Alan ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CREATININE; ZANAMIVIR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; SIDE EFFECT; URINARY EXCRETION;

EID: 0032997873     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199936001-00002     Document Type: Article

References (4)

1. 1. Von Itzstein M, Wu W-Y, Kok GB, et al. Rational design of potent sialidase based inhibitors of influenza virus replication. Nature 1993; 363: 418-23
2. 2. Whittington A, Bethell R. Recent developments in the antiviral therapy of influenza. Expert Opin Ther Pat 1995; 5: 793-803
3. 3. Woods JM, Bethell RC, Coates JAV, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37: 1473-9
4. 4. Cass LMR, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999; 36 Suppl. 1: 1-11